- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04868695
Subjective and Objective Outcome of ESS in CRSwNP
Subjective and Objective Outcom Eof Endoscopic Sinus Surgery in Patients With Chronic Rhinosinusitis With Nasal Polyps
(A): Beidseitige Fronto-Spheno-Ethmoidektomie mit Erweiterung des natürlichen Zuganges zur Stirnhöhle (Draf Typ II): Unter einem Draf Typ II Zugang versteht man die Erweiterung des natürlichen Zuganges zur Stirnhöhle mit Entfernung des Bodens der Stirnhöhle zwischen der Lamina papyracea zur Augenhöhle und der mittleren Nasenmuschel.
(B): Beidseitige Fronto-Spheno-Ethmoidektomie mit maximaler Erweiterung des Zuganges zur Stirnhöhle (Draf Typ III): Unter einem Draf Typ III verste. (C) Beidseitige Spheno-Ethmoidektomie: Abtragung des Processus uncinatus, die Eröffnung der Kieferhöhle, die Eröffnung des vorderen und hinteren Siebbeinsystems und die Eröffnung der Keilbeinhöhle.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
(A): Beidseitige Fronto-Spheno-Ethmoidektomie mit Erweiterung des natürlichen Zuganges zur Stirnhöhle (Draf Typ II): Unter einem Draf Typ II Zugang versteht man die Erweiterung des natürlichen Zuganges zur Stirnhöhle mit Entfernung des Bodens der Stirnhöhle zwischen der Lamina papyracea zur Augenhöhle und der mittleren Nasenmuschel.
(B): Beidseitige Fronto-Spheno-Ethmoidektomie mit maximaler Erweiterung des Zuganges zur Stirnhöhle (Draf Typ III): Unter einem Draf Typ III verste. (C) Beidseitige Spheno-Ethmoidektomie: Abtragung des Processus uncinatus, die Eröffnung der Kieferhöhle, die Eröffnung des vorderen und hinteren Siebbeinsystems und die Eröffnung der Keilbeinhöhle.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Michael B Soyka, MD
- Phone Number: 0432531460
- Email: rhinologie@usz.ch
Study Contact Backup
- Name: Christian Meerwein, MD
- Phone Number: 0432531460
- Email: rhinologie@usz.ch
Study Locations
-
-
-
Zurich, Switzerland, 8091
- Recruiting
- Zurich University Hospital
-
Contact:
- Michael Soyka, Dr.med.
- Phone Number: +41 44 255 11 11
- Email: michael.soyka@usz.ch
-
Principal Investigator:
- Michael Soyka, Dr.med.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Symptomatic CRSwNP patients without improvement after conservative treatment for at least 6 months Extent of disease at least Davos Polyp Score ≥ 4 points Age 18-65 years Signed consent
Exclusion Criteria:
- Previous sinunasal surgery High resolution paranasal sinus CT shows other pathology (e.g. mucocele) Incapable of judgement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bilateral Spheno-Ethmoidectomy:
|
1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3
|
Experimental: Bilateral Fronto-Spheno-Ethmoidectomy + Draf 2b
|
1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3
|
Experimental: Draf Typ 3
|
1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nasal Polyp Score
Time Frame: 12 months
|
Nasal Polyps
|
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- ID 2020-00322
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CRS
-
University of PennsylvaniaRecruitingCRS - Cytokine Release Syndrome | HLHUnited States
-
Kafrelsheikh UniversityRecruiting
-
Hillel Yaffe Medical CenterThe TechnionCompleted
-
Rigshospitalet, DenmarkNot yet recruitingHematologic Cancer | CRS - Cytokine Release Syndrome
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI)CompletedCardiorenal Syndrome (CRS)United States
-
University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting
-
Novartis PharmaceuticalsCompletedCytokine Release Syndrome (CRS) in Patients With COVID-19-induced PneumoniaSpain, United States, United Kingdom, Russian Federation, Italy, France
-
PfizerBiohaven Pharmaceutical Holding Company Ltd.Active, not recruitingChronic Rhinosinusitis (CRS) With and Without Nasal PolypsUnited States
-
CytoSorbents, IncRecruitingSepsis | Burns | Septic Shock | Trauma | Infectious Disease | Pancreatitis | Acute Respiratory Distress Syndrome | Liver Transplant; Complications | Drug Overdose | Acute Liver Failure | Cardiogenic Shock | Rhabdomyolysis | Acute on Chronic Liver Failure | Hemophagocytic Lymphohistiocytoses | Extracorporeal Life Support and other conditionsSpain, Italy, Germany, Portugal
Clinical Trials on 1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3
-
Ibrahim Talal ElshamyRecruitingChronic Rhinosinusitis With Nasal Polyps | Endoscopic Frontal Sinus Surgery | Draf III | Draf I or IIaEgypt
-
Beijing Tongren HospitalCompletedChronic Rhinosinusitis (Diagnosis) | Surgery
-
University of CopenhagenNordea-fondenCompletedGlucose Intolerance | Insulin SensitivityDenmark
-
Hospices Civils de LyonCompletedCardiometabolic RiskFrance
-
Seoul National University HospitalUnknown
-
Assistance Publique Hopitaux De MarseilleUnknown
-
JW PharmaceuticalCompletedHealthyKorea, Republic of
-
Shenzhen TargetRx, Inc.First Affiliated Hospital Bengbu Medical CollegeCompleted
-
PfizerCompletedObesityUnited States, Taiwan, Canada, Japan